Previous Next

2024-03-05

Pomalidomide in relapsed/refractory multiple myeloma

Hematology

In this study, researchers evaluated the efficacy and safety of pomalidomide in the combined treatment of relapsed/refractory multiple myeloma. In all, data from 31 clinical trials were reviewed, involving a total of 4,776 patients. Combination regimens with pomalidomide showed good clinical efficacy, particularly the combination of pomalidomide and dexamethasone. In terms of safety, the most frequent grade ≥ 3 hematological adverse events were neutropenia (41%) and anemia (20%). Non-hematological adverse events were pneumonia (14%) and infection/febrile neutropenia (14%). While the clinical efficacy of pomalidomide appears interesting, its hematological toxicity calls for particular vigilance.

Source(s) :
Source(s) : Ying Luo et al. Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis. Expert Rev Hematol. 2024 Feb 29. ;

Last press reviews


Eat without fear: anti-ige antibody omalizumab, a new weapon against food allergies

#Omalizumab #FoodAllergies #IgE #Anaphylaxis #Immunotherapy  ...

Vitamin D and tuberculosis: an overestimated protection?

By Ana Espino | Published on July 18, 2025 | 2 min read

Outdoor temperature and severe hyponatremia: a growing threat in the age of climate change

By Lila Rouland | Published on July 17, 2025 | 3 min read  ...